Emergent Biosolutions Net Profit Margin 2007-2021 | EBS

Emergent Biosolutions net profit margin from 2007 to 2021. Net profit margin can be defined as net Income as a portion of total sales revenue.
Emergent Biosolutions Net Profit Margin Historical Data
Date TTM Revenue TTM Net Income Net Margin
2021-09-30 $1.65B $0.23B 13.73%
2021-06-30 $1.71B $0.30B 17.55%
2021-03-31 $1.71B $0.39B 22.74%
2020-12-31 $1.56B $0.31B 19.60%
2020-09-30 $1.33B $0.17B 12.53%
2020-06-30 $1.26B $0.17B 13.49%
2020-03-31 $1.11B $0.07B 6.05%
2019-12-31 $1.11B $0.05B 4.88%
2019-09-30 $1.02B $0.00B 0.39%
2019-06-30 $0.88B $-0.02B -2.05%
2019-03-31 $0.86B $0.04B 4.91%
2018-12-31 $0.78B $0.06B 8.05%
2018-09-30 $0.71B $0.10B 14.16%
2018-06-30 $0.68B $0.11B 16.59%
2018-03-31 $0.56B $0.07B 12.10%
2017-12-31 $0.56B $0.08B 14.80%
2017-09-30 $0.52B $0.09B 16.57%
2017-06-30 $0.51B $0.07B 14.23%
2017-03-31 $0.50B $0.06B 11.33%
2016-12-31 $0.49B $0.05B 10.43%
2016-09-30 $0.48B $0.05B 9.83%
2016-06-30 $0.49B $0.06B 12.78%
2016-03-31 $0.53B $0.09B 16.67%
2015-12-31 $0.49B $0.06B 12.68%
2015-09-30 $0.45B $0.06B 13.11%
2015-06-30 $0.43B $0.04B 10.23%
2015-03-31 $0.41B $0.04B 8.45%
2014-12-31 $0.40B $0.04B 9.16%
2014-09-30 $0.40B $0.02B 5.50%
2014-06-30 $0.35B $0.01B 3.70%
2014-03-31 $0.32B $0.02B 5.57%
2013-12-31 $0.31B $0.03B 9.62%
2013-09-30 $0.31B $0.03B 10.03%
2013-06-30 $0.29B $0.03B 8.71%
2013-03-31 $0.28B $0.02B 8.36%
2012-12-31 $0.28B $0.02B 8.51%
2012-09-30 $0.30B $0.04B 12.54%
2012-06-30 $0.29B $0.03B 11.15%
2012-03-31 $0.31B $0.04B 12.46%
2011-12-31 $0.27B $0.02B 8.76%
2011-09-30 $0.27B $0.02B 7.81%
2011-06-30 $0.28B $0.03B 11.27%
2011-03-31 $0.26B $0.03B 10.85%
2010-12-31 $0.29B $0.05B 18.18%
2010-09-30 $0.24B $0.03B 12.66%
2010-06-30 $0.21B $0.02B 8.74%
2010-03-31 $0.22B $0.02B 10.60%
2009-12-31 $0.24B $0.03B 13.19%
2009-09-30 $0.22B $0.03B 12.90%
2009-06-30 $0.23B $0.04B 16.02%
2009-03-31 $0.20B $0.02B 11.94%
2008-12-31 $0.18B $0.02B 11.17%
2008-09-30 $0.23B $0.05B 20.17%
2008-06-30 $0.22B $0.04B 18.18%
2008-03-31 $0.20B $0.03B 16.50%
2007-12-31 $0.18B $0.02B 12.57%
2007-09-30 $0.18B $0.02B 11.67%
2007-06-30 $0.18B $0.02B 12.36%
2007-03-31 $0.17B $0.02B 14.46%
2006-12-31 $0.15B $0.02B 14.47%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.380B $1.555B
Emergent BioSolutions Inc. is strongly committed to the highest standards of ethical conduct and corporate governance. These standards are consistent with their corporate culture. The company understands that adhering to sound principles of corporate governance is critical to earning and maintaining the trust of their customers, employees and shareholders. The foundation of the corporate governance principles and practices are built on their reputation for openness, integrity and accountability. These are the principles that guide Emergent BioSolutions everyday. They have in place policies and practices to ensure that their Company is managed with integrity and in their shareholders' best interests. In addition, they are committed to meeting the requirements of federal and state law and the rules of the New York Stock Exchange.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $141.747B 8.96
Bio-Rad Laboratories (BIO.B) United States $17.038B 34.58
QIAGEN (QGEN) Netherlands $10.791B 18.27
Biohaven Pharmaceutical Holding (BHVN) United States $7.896B 0.00
Arcus Biosciences (RCUS) United States $2.057B 0.00
Myovant Sciences (MYOV) United Kingdom $1.157B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.011B 0.00
Zymeworks (ZYME) Canada $0.386B 0.00
Ambrx Biopharma (AMAM) United States $0.188B 0.00
SQZ Biotechnologies (SQZ) United States $0.178B 0.00
Enzo Biochem (ENZ) United States $0.154B 19.88